| pubmed-article:1676628 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1676628 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:1676628 | lifeskim:mentions | umls-concept:C0001924 | lld:lifeskim |
| pubmed-article:1676628 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:1676628 | lifeskim:mentions | umls-concept:C0030817 | lld:lifeskim |
| pubmed-article:1676628 | lifeskim:mentions | umls-concept:C0301869 | lld:lifeskim |
| pubmed-article:1676628 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:1676628 | pubmed:dateCreated | 1991-8-14 | lld:pubmed |
| pubmed-article:1676628 | pubmed:abstractText | D-penicillamine (D-PEN) is incompletely recovered during short-term balance studies, despite rapid elimination of D-PEN and its low molecular weight metabolites. Urinary excretion of metabolites of D-PEN also persists long after cessation of chronic therapy. A study was performed to determine whether the formation and later breakdown of a stable disulfide between D-PEN and plasma albumin could explain these aspects of D-PEN pharmacokinetics. Five human volunteers received D-penicillamine, 250 mg orally, daily for 21 days. Plasma concentration-time profiles for D-PEN and D-PEN-albumin disulfide (D-PEN-albumin) were determined during the first day and pre-dose concentrations were measured on five further occasions. The pharmacokinetics of D-PEN on the first day were similar to those reported previously. No D-PEN was found in any of the pre-dose specimens. The concentration of D-PEN-albumin rose rapidly during the first day, with an estimated 8.6% of the bioavailable D-PEN being transformed to D-PEN-albumin. Pseudo-steady-state concentrations of D-PEN-albumin were achieved in three subjects at between 14 and 21 days. The mean trough concentration of D-PEN-albumin at 21 days (19.5 microM) exceeded the peak concentration of D-PEN (during the first day) by 5.7-fold. The terminal elimination half-life of D-PEN-albumin was 1.65 +/- 0.29 days, which compared with an elimination half-life of 59 +/- 8.4 min for D-PEN.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:1676628 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1676628 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676628 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1676628 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676628 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1676628 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1676628 | pubmed:issn | 0090-9556 | lld:pubmed |
| pubmed-article:1676628 | pubmed:author | pubmed-author:DayR ORO | lld:pubmed |
| pubmed-article:1676628 | pubmed:author | pubmed-author:MurphyB RBR | lld:pubmed |
| pubmed-article:1676628 | pubmed:author | pubmed-author:JoyceD ADA | lld:pubmed |
| pubmed-article:1676628 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1676628 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:1676628 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1676628 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1676628 | pubmed:pagination | 309-11 | lld:pubmed |
| pubmed-article:1676628 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1676628 | pubmed:meshHeading | pubmed-meshheading:1676628-... | lld:pubmed |
| pubmed-article:1676628 | pubmed:meshHeading | pubmed-meshheading:1676628-... | lld:pubmed |
| pubmed-article:1676628 | pubmed:meshHeading | pubmed-meshheading:1676628-... | lld:pubmed |
| pubmed-article:1676628 | pubmed:meshHeading | pubmed-meshheading:1676628-... | lld:pubmed |
| pubmed-article:1676628 | pubmed:meshHeading | pubmed-meshheading:1676628-... | lld:pubmed |
| pubmed-article:1676628 | pubmed:meshHeading | pubmed-meshheading:1676628-... | lld:pubmed |
| pubmed-article:1676628 | pubmed:meshHeading | pubmed-meshheading:1676628-... | lld:pubmed |
| pubmed-article:1676628 | pubmed:meshHeading | pubmed-meshheading:1676628-... | lld:pubmed |
| pubmed-article:1676628 | pubmed:meshHeading | pubmed-meshheading:1676628-... | lld:pubmed |
| pubmed-article:1676628 | pubmed:meshHeading | pubmed-meshheading:1676628-... | lld:pubmed |
| pubmed-article:1676628 | pubmed:articleTitle | The pharmacokinetics of albumin conjugates of D-penicillamine in humans. | lld:pubmed |
| pubmed-article:1676628 | pubmed:affiliation | Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Australia. | lld:pubmed |
| pubmed-article:1676628 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1676628 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1676628 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1676628 | lld:pubmed |
